Search
![](https://static.wixstatic.com/media/nsplsh_0294f019e88a4c0bb5c673cf7477b99a~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/nsplsh_0294f019e88a4c0bb5c673cf7477b99a~mv2.jpg)
![Gilead: First Regulatory Approval of HIV Sunlenca® (Lenacapavir) the Only Twice-Yearly HIV Treatment](https://static.wixstatic.com/media/nsplsh_0294f019e88a4c0bb5c673cf7477b99a~mv2.jpg/v1/fill/w_399,h_300,fp_0.50_0.50,q_90,enc_auto/nsplsh_0294f019e88a4c0bb5c673cf7477b99a~mv2.jpg)
Sharan Murugan
- Aug 24, 2022
- 1 min
Gilead: First Regulatory Approval of HIV Sunlenca® (Lenacapavir) the Only Twice-Yearly HIV Treatment
On 22-August-2022, Sunlenca (lenacapavir) is an injectable HIV medication developed by Gilead Sciences that has been approved to market...
63 views0 comments